INTRODUCTION
Bronchiectasis is increasingly recognised as both a primary disease and as a complication of other common diseases such as asthma and chronic obstructive pulmonary disease (COPD). There is a paucity of data on the epidemiology, pathophysiology, and optimal treatment approaches in this patient population. Data does suggest, however, that the incidence of bronchiectasis is increasing, with a corresponding increase in mortality rates. Marked heterogeneity exists in the aetiologies of bronchiectasis and these may result in different therapeutic targets. Significant knowledge gaps remain and there is a continuing need to systematically coordinate our research endeavours to enable us to deliver a step-wise change in bronchiectasis management from empirical to evidence-based therapies. Networks are developing to capture large patient cohorts, allowing better understanding of the disease process and its management (e.g. www.bronchiectasis.eu and BronchUK, www.bronch.ac.uk). Multidisciplinary and cross-national efforts in epidemiology, microbiology, genetics, immunology, basic science, and epithelial biology in conjunction with the pharmaceutical industry will help to tackle these knowledge gaps and deliver effective new therapies to the clinic. Selected research areas that such collaborative efforts may undertake are discussed in this article.
DEFINITION AND DIAGNOSIS OF BRONCHIECTASIS
Bronchiectasis, also referred to as non-cystic fibrosis bronchiectasis, is characterised by irreversible airway dilatation with clinical features including cough, chronic sputum production, haemoptysis, dyspnoea, and chronic rhinosinusitis. Patients report recurrent hospital admissions, reduced quality of life, and fatigue. [1] [2] [3] [4] . The "vicious cycle" hypothesis describes how a combination of host susceptibility and environmental insult leads to progressive airway damage and dilatation 5 . Defects in host immune response can also contribute to chronic infection and inflammation 6 .
Whilst bronchiectasis is quite frequently seen in COPD and in some cases of chronic asthma, it is unclear if there is causality or co-association between these conditions. Recognised aetiologies include post-infection, immunodeficiency syndromes, inflammatory bowel disease, connective tissue diseases, primary ciliary dyskinesia, Young's syndrome, and inhalation of a foreign body. A significant proportion of cases, up to 50%, will have idiopathic bronchiectasis [7] [8] [9] [10] . Investigations to identify associated conditions may include genetic testing for cystic fibrosis, Aspergillus precipitins, immunological profile, and sputum microbiology 9 . Defining the aetiology leads to management changes for both children and adults with bronchiectasis 7, 10, 11 .
To confirm clinical suspicions, high-resolution computed tomography scanning (HRCT) is required 12 . Studies acknowledge that a clinical scenario highly suggestive of bronchiectasis may not correlate with a "positive" HRCT, which raises questions about the links between clinical symptoms and the pathophysiological processes involved 7, 8 . It has also been shown in two case-series that approximately 15% of radiologically diagnosed patients had their bronchiectasis diagnosis refuted on re-read of their scans 8, 13 .
The comparison of airway and accompanying artery diameter in order to establish presence of airway dilatation has been described pathologically 14 . The same comparison is used to look for airway dilatation on HRCT scans 15 . Bronchial wall thickening is also well described in bronchiectasis imaging ( Fig. 1 and 2 ). When bronchiectasis and COPD co-exist or overlap, understanding which process drives this is challenging. Gatheral et al. studied the impact of COPD-related bronchiectasis and showed the presence of bronchiectasis to be associated with increased infections and hospitalisations, regardless of bronchial wall Many clinicians report that patients with primary ciliary dyskinesia, including Kartagener's, run a milder course than other aetiologies. To date convincing multicentre data confirming this is rare. As more genetic understanding of primary ciliary dyskinesia develops, it remains to be understood if different genetic mutations leading to primary ciliary dyskinesia leads to different prognoses.
Figure 2.
What are the minimal investigation sets required to define aetiology? This computed tomography scan demonstrates emphysema and bronchiectasis, suggesting the underlying aetiology may be bronchiectasis and COPD overlap syndrome. However, when referred to a specialist centre because of recurrent exacerbations, "basic tests" were undertaken. These and the clinical history revealed a childhood onset of symptoms and panhypogammaglobulinaemia with normal alpha-1 antitrypsin levels. This suggested a possible immunodeficiency associated bronchiectasis with co-existent smoking related COPD. Treatment with intravenous immunoglobulin markedly reduced infective exacerbation rates.
thickness 16 . Difficulty remains in defining COPD-driven bronchiectasis or idiopathic bronchiectasis in an ex-or current smoker. A catch-all term, bronchiectasis and COPD overlap syndrome (BCOS), has been suggested 17 (Table 1 ).
EPIDEMIOLOGY
Reported rates of bronchiectasis are likely to be inaccurate due to misdiagnosis (as other common respiratory disorders, e.g. asthma or COPD) and missed diagnosis (e.g. with overlapping diagnoses such as BCOS and asthma-bronchiectasis overlap syndrome [ABOS]). Data across multiple healthcare systems suggest that the prevalence is increasing [18] [19] [20] [21] . Recent population-based estimates of prevalence in Germany suggested an overall rate of 67/100,000, increasing to 228/100,000 in men aged 75-84 20 . Prior data from the USA support these findings, with an even higher overall annual prevalence of 370/100,000 person-years and 537/100,000 person-years in women aged 80-84 21 . We are unsure if rising prevalence is due to increased pick-up rates with greater access to HRCT scanning, or if it represents a real increase in disease burden. Irrespective of the cause of increasing rates of bronchiectasis, we are still left with a conundrum: why is bronchiectasis not rapidly declining with improving health, nutrition, access to childhood vaccination, and antibiotic therapy? 4. What is the minimal set of aetiological investigations? (Fig. 2) 5. Does HRCT have any role in monitoring response to treatment? (Fig. 3) 6. Does air trapping/mosaicism pattern on HRCT predict a better response to anti-inflammatory treatments? (Fig. 4 Establishing aetiological causality in bronchiectasis also presents on-going uncertainties: separating idiopathic bronchiectasis from post-infectious bronchiectasis is challenging. Accuracy in categorisation is important as some aetiological subgroups encountered in clinical practice are excluded from interventional studies 22, 23 . A recent UK primary care database study suggested that HIV infection was a more common aetiological cause of bronchiectasis than previously reported 21 . This may reflect greater rates of HRCT scanning in this population, perhaps advocating wider use of HRCT in other "at-risk" groups. High rates of bronchiectasis in COPD have also been reported (as high as 40%), yet this
is likely to be influenced by which sub-population of COPD patients are investigated, i.e. "chronic bronchitis recurrent exacerbators" or all other phenotypes of COPD (such as emphysema without exacerbations) 9, 16 . The fact that the conditions known to overlap with bronchiectasis (COPD and asthma) are so prevalent could translate into a large increase in identification of cases of bronchiectasis.
Several unknowns are listed in table 2.
PROGNOSIS
Until recently, prognosis data has been dominated by single-centre studies, often from specialised centres. Available data from across the UK suggests an increasing mortality rate at 3% per year 22 . Two prognostic scoring indices providing estimates of mortality and hospitalisations over a 4-5 year period have recently been published: the FACED score (Forced expiratory volume 1 second, Age, Colonisation by Pseudomonas aeruginosa, Extent [number of lobes affected] and Dyspnoea, Spain) and the Bronchiectasis Severity Index (BSI, Edinburgh). The latter was internationally validated across four centres (UK, Belgium, and Italy). It has many components similar to the FACED with additional factors consisting of weighting for prior healthcare use and persistent infection with "other pathogens" 24, 25 . Neither, however, has been tested outside of Europe or in developing nations and we do not know how interventions such as Pseudomonas eradication may alter such prognostic indices (Table 3) .
PATHOGENESIS AND MICROBIOLOGY
Cole's continuous and self-perpetuating vicious cycle hypothesis provides a useful Although this is relatively common in bronchiectasis, little is known about the mechanisms leading to this appearance in some but not all. A further unknown is whether this computed tomography appearance predicts better responses to inhaled corticosteroids or anti-inflammatory macrolides.
model of bronchiectasis pathophysiology to this day 5 . Treatment is targeted at interrupting the interconnecting processes of failed mucus clearance, airway bacterial colonisation, airway inflammation, and airway structural damage in an attempt to break this cycle and prevent disease progression 26, 27 .
Airway inflammation is dominated by neutrophils, with impaired mucociliary clearance and failure of neutrophil opsonophagocytic killing 6 . Since these neutrophils are believed to be normal prior to their arrival in the airway, it is likely that the airway inflammatory milieu itself impairs bacterial clearance [27] [28] [29] . Neutrophil elastase is associated with reduced opsonisation of pathogens, further promoting pro-inflammatory cytokine release. Neutrophil elastase also slows ciliary beat frequency and promotes mucus hypersecretion via activation of the MUC5AC gene 30, 31 . Further mechanisms of immune dysfunction include failure to clear apoptotic cells and T-cell infiltration, particularly Th17 cells 32 . Much more work, however, is needed before targeted anti-cytokine therapies can be trialled.
Patients with bronchiectasis frequently develop acute infective pulmonary exacerbations characterised by symptoms of fever, purulent sputum, and dyspnoea, with associated adverse effects on both morbidity and quality of life. Frequent exacerbations may contribute to the progressive decline of lung function, although both the aetiology and pathophysiology of exacerbations remains poorly understood. Studies using classical microbial culture techniques in stable state bronchiectasis report Haemophilus influenzae (14-47% of cases), Pseudomonas aeruginosa (5-31%), and Streptococcus pneumoniae (2-14%) as the most frequently isolated pathogens 10, 33, 34 .
Bronchiectatic airways may become "colonised" by P. aeruginosa with "repeated positive sputum cultures over a defined period of time". Conflicting data exist on the independent contribution of P. aeruginosa to long-term prognosis. Whether P. aeruginosa drives disease progression or is simply a marker of existing severe disease remains in question. A recent meta-analysis of 3,683 bronchiectasis patients demonstrated P. aeruginosa colonisation in 21.4% of patients, which was associated with a threefold increase in mortality and a sevenfold increase in hospitalisation rates 35 . In this analysis, eight different methods of defining P. aeruginosa colonisation in bronchiectasis studies were identified. The word "colonisation" is misleading and perhaps "persistent infection" should be adopted more widely.
Although there are numerous studies in cystic fibrosis (CF) regarding the transmissibility of epidemic strains of P. aeruginosa and Mycobacterium abscessus, cross-infection data in bronchiectasis are very limited [36] [37] [38] . The 2010 guidelines failed to comment on this evidence gap, leaving it unclear as to whether or not bronchiectasis patients with P. aeruginosa should be segregated as is recommended in CF infection control guidelines 9 . Most cross-infection studies in bronchiectasis are single centre and focus on P. aeruginosa, with limited longitudinal sampling [39] [40] [41] . These often lack a robust description of the clinical environment, e.g. are facilities shared with patients who have CF and carry known CF epidemic strains? In a case series of 40 patients from a UK adult bronchiectasis clinic without strict segregation, using two genotyping techniques to cross validate findings, no single common "epidemic strain" was found 39 . However, certain common strains found widely within the natural environment, e.g. Pseudomonas clone C, did infect patients raising the possibility of environmental acquisition in the bronchiectasis population 39 .
Pujana et al. examined 16 patients with 64 P. aeruginosa isolates. Despite the limited discrimination potential of DNA fingerprinting, cross-infection, or common source, acquisition was absent 40 . In another study of 125 isolates taken from 31 patients attending a bronchiectasis clinic in Spain, pulsed field gel electrophoresis suggested that certain strains may be predominant within a clinical setting 41 .
On balance, there are no strong data suggesting widespread P. aeruginosa epidemic strains as a cause of clinical decline in bronchiectasis; why this is so different to CF remains unknown.
Whilst P. aeruginosa colonisation is associated with reduced lung function, a longitudinal study demonstrated P. aeruginosa infection across all stages of airflow limitation, highlighting the importance of rigorous sputum surveillance protocols in all bronchiectasis patients, even those with "mild" airflow limitation 42 .
Huge variations in definitions and therapies for bacterial eradication are noted between different healthcare systems and countries. Is it possible to fully eradicate P. aeruginosa? One retrospective study suggested that 34% of P. aeruginosa colonised patients subsequently became culture negative on follow-up; however, it is difficult to determine if this was true eradication or failure of successful in vitro culture using classical techniques 42 . The capability of P. aeruginosa to form biofilms protects it from both the immune system and systemically delivered antibiotics. It also rapidly adapts to chronic infection in the lung and readily develops antimicrobial resistance 27 .
The BTS guidelines for bronchiectasis recommend eradication treatment for new isolation of P. aeruginosa 8 . However, some patients may spontaneously clear the organism without treatment. A recent randomised controlled trial evaluating the efficacy of three months nebulised tobramycin following intravenous antibiotics on initial isolation of P. aeruginosa, showed Pseudomonas-free rates of 54.5% in treatment group versus 29.4% in placebo group 43 . These eradication rates are, however, significantly lower than those reported in CF, further confirming the different pathobiology of these two conditions.
We have few data on microbiology outside Europe and Australasia, and there is also a definite lack of data describing the impact of organisms other than P. aeruginosa in bronchiectasis, in particular in those colonised with the most common bronchiectasis pathogens such as H. influenzae 35 . Recent reports suggest that Haemophilus-infected patients do have a worse outcome compared to non-colonised patients, but to a lesser extent than P. aeruginosa 35 . A recent post-hoc analysis of the trial suggested that in patients without P. aeruginosa airway infection, erythromycin did not significantly reduce exacerbations and actually promoted displacement of H. influenzae by more macrolide-tolerant pathogens including P. aeruginosa. These findings argue for a cautious approach to chronic macrolide use in patients without P. aeruginosa airway infection 44, 45 .
Significant recent advances in our understanding of bronchiectasis have arisen through culture-independent microbiological techniques that allow a comprehensive analysis of polymicrobial bacterial communities in the lung 27 . Detection of uncultivable microorganisms has challenged our understanding pathogenesis, progression, and management of bronchiectasis. These technologies reveal colonisation with organisms previously not recognised by culture-based studies like Veilonella sp., Prevotella sp. and Neisseria spp 50 . Loss of microbiome diversity, with dominance of one or a few species, is associated with worse lung function and increased exacerbations 46, 47 . An inverse relationship between the abundance of P. aeruginosa and that of H. influenzae within the bronchiectasis lung bacterial community suggests a progression in microbial states 47 .
The role of viruses and air pollution, whilst described in other disease areas, is poorly studied in bronchiectasis. Exacerbations in bronchiectasis are frequently managed with antibiotics; however, viral infections may also be significant in many cases. Recent data suggests that respiratory viruses may play a crucial role in triggering bronchiectasis exacerbations 48 (Table 4) .
TREATMENT
There are a number of widely used current therapies in bronchiectasis; to our knowledge none are specifically licensed for the treatment of bronchiectasis. We will limit discussion to antimicrobials, though note there are many unknowns in the utility and best regimens for anti-inflammatory treatments, physiotherapy, and mucolytics in bronchiectasis. Many therapies developed and now used for CF do not readily translate across into bronchiectasis, e.g. nebulised aztreonam, now licensed for CF, has two "negative" phase III trials in bronchiectasis 49 . This was also seen for the inhaled mucolytic mannitol 50 . It is entirely plausible that good therapies for bronchiectasis have been inadvertently but inappropriately discarded due to unintended sub-optimal trial designs translated over from the CF literature.
Perhaps the greatest evidence of efficacy for treatments currently used in bronchiectasis is for prolonged or long-term macrolide (LTM) antibiotics with three large scale studies consistently showing an effect in exacerbation reduction with either long-term azithromycin 500 mg thrice weekly, 250 mg daily, or 400 mg twice daily of erythromycin (BLESS, BAT and EMBRACE trials) [51] [52] [53] . Several recent meta-analyses, including these studies and various smaller scale studies, have confirmed the role for LTMs in exacerbation prevention [54] [55] [56] [57] . There were no clear effects on pathogen clearance or eradication, but statistical if not clinically significant improvements in forced expiratory volume in one second (FEV 1 ) and quality of life measures were observed. Unfortunately, a consistent theme, where measured, was the statistically significant increase in macrolide resistance. The evidence for macrolides in preventing exacerbations in recurrent exacerbators is strong. The role of LTM in patients with high symptom burdens but without frequent exacerbations is unclear. In our experience, many of these report symptomatic improvement with LTM. However, many questions remain over the use of long-term macrolides (Table 5) .
Chronic inhalational antibiotics (CIA) are widely used in bronchiectasis and until recently the evidence base was scant. A single-centre single-blind study of gentamicin produced marked reductions in exacerbations; multicenter double-blind, follow-on studies may help truly define the utility of this therapy in daily practice 58 . Data from a large multicenter international trial of nebulised ultrafine colistin delivered by an intelligent breath-activated nebuliser was particularly notable, even though the study failed to reach its primary endpoint. This landmark study 6. Should chronic macrolide therapy be restricted to patients with frequent exacerbations and high severity index scores or is there a rationale for using them in highly symptomatic but non-exacerbating "lower risk" patients?
7. How do we define partial response to macrolides? Do patients not responding to one macrolide respond to switching to an alternative macrolide or dose escalation?
8. Can LTM treatment holidays be applied to patients across a range of disease severities in spring/summer months?
9. Do the differing macrolides offer similar efficacy but differing adverse event profiles, e.g. ototoxicity, cardiac conduction defects and/or resistance induction rates?
Whilst there are a number of good quality studies of long-term macrolides in bronchiectasis, there are still several unanswered questions. LTM: long-term macrolide.
demonstrated a significant proportion of trials participants were non-compliant. When a per protocol analysis was conducted, limiting the analysis to patients defined as compliant at 80% or more of prescribed therapy, there was a significant exacerbation reduction effect. These observations, along with others, suggest we have issues in defining the appropriate target population, the optimal outcome measures, and in ensuring that non-compliance does not impair study outcomes 59 .
Phase II studies have suggested a possible role for dry powder inhaled ciprofloxacin and nebulised liposomal ciprofloxacin, with a reduction in bacterial load 60, 61 . Both are now in phase III development programs.
One key challenge will be to understand the implications of "resistant" strains in CIA therapy. Firstly, the breakpoints established for antimicrobials that are currently used to define resistance or sensitivity probably have little relevance to the biofilm mode of growth, nor the very high concentrations possible within the lung with CIA. Secondly, longterm CIA therapy will likely select a sub-population of resistant bacteria. If, however, the suppression of sensitive strains results in a clinically meaningful reduction in total bacterial load, the emergence (or selection) of resistant strains may be acceptable.
There are significant uncertainties in the role of either inhaled or oral long-term antibiotics. There are no studies randomising patients to LTM as compared to CIA. One uncertainty for the future will be where such new therapies fit in in comparison to long-term macrolides? Commonly, there is a patient preference for LTM, given these are easier to fit into a treatment regimen.
Clinicians may well however prefer to limit LTM use and target pathogens with inhaled therapies. Shared decision making will ultimately improve patient adherence (Table 6 ).
ADHERENCE AND EDUCATION
For some patients with bronchiectasis, multiple medical treatments may be required. Some of these, such as nebulised treatments and airway clearance regimes, can be particularly burdensome in terms of a regular time commitment. It makes sense that for treatments to be effective, they need to be taken as prescribed, but what do we know about deviations from the prescribed regime and what effect this has in bronchiectasis? One recent study looked at treatment adherence in bronchiectasis and found that over a one-year period just over 50% of participants were adherent to inhaled antibiotics and other respiratory treatments and 41% adherent to airway A high degree of adherence seems to be beneficial, at least when it comes to inhaled antibiotics, so promoting treatment adherence and educating patients about this is important. The BTS guidelines recommend patient education about treatments and self-management, but no specific information or educational packages are recommended 9 . Qualitative studies highlight that patients feel that lack of information is one of the barriers to self-management and describe the importance of information in improving patients' confidence and in developing the skills to live with and manage their condition 63, 64 . Factors predicting adherence to treatment in bronchiectasis include patients' beliefs about treatments, perceived treatment burden, and number of prescribed treatments 65 .
Further work to develop a behaviour change intervention to promote adherence to treatment in bronchiectasis offers hope 66 .
Developing an understanding of patients' and their carer givers' information and education needs and how these could be addressed may offer a key advance 67 . A variety of packages have been developed for use in COPD, yet there remains to be an evidenced-based intervention designed for use in this patient population [68] [69] [70] .
CONCLUSIONS
Patients with bronchiectasis and clinicians managing them are unable to achieve optimal patient care until major gaps in our understanding of the disease pathophysiology, prognosis, and optimal treatment regimens are advanced. Collaborative working and harnessing the enthusiasm and engagement of a patient population that has been frustrated by delays in diagnosis and empirical treatment into both observational and interventional studies will be crucial to achieving this. After the recently noted increases in bronchiectasis prevalence, the renewed enthusiasm from the life sciences industry for intervention studies in bronchiectasis and international collaborative efforts in bronchiectasis are both timely and desperately needed.
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